Trial Profile

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HuMax IL8 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary) ; Celecoxib
Indications Adenocarcinoma; Colon cancer
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms NICHE; NICHE-2; NICHE-3

19 Sep 2025 Planned End Date changed from 1 Dec 2024 to 1 Mar 2032.
19 Sep 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2032.
26 May 2025 Planned number of patients changed from 268 to 353.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com